These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 16680230)

  • 21. Mortality rate during interferon alfa-ribavirin combination therapy of chronic hepatitis C.
    Soza A; Hoofnagle JH
    Hepatology; 2003 Jul; 38(1):267. PubMed ID: 12830010
    [No Abstract]   [Full Text] [Related]  

  • 22. [Ribavirin: a new drug in the treatment of chronic hepatitis C].
    Salmerón J
    Gastroenterol Hepatol; 1997; 20(7):363-5. PubMed ID: 9377236
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of interferon therapy on fatty acid saturation index in hepatitis C virus infection.
    Abdel Aziz MT; Abdel-Ghaffar Y; Fouad HH; Abdel Aziz DM; el-Magd AA
    East Mediterr Health J; 2001; 7(4-5):779-86. PubMed ID: 15332779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An intervention to prevent symptoms associated with hepatitis C: a pilot study.
    Zucker DM
    Appl Nurs Res; 2010 May; 23(2):116-20. PubMed ID: 20421000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of nitric oxide (NO) in interferon-alpha therapy for hepatitis C.
    Hokari A; Zeniya M; Esumi H; Ishikawa T; Kurasima Y; Toda G
    J Infect; 2005 Jul; 51(1):47-53. PubMed ID: 15979491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ribavirin for chronic hepatitis C: and the mystery goes on.
    Brillanti S; Mazzella G; Roda E
    Dig Liver Dis; 2011 Jun; 43(6):425-30. PubMed ID: 21093391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Community-based treatment for chronic hepatitis C in drug users: high rates of compliance with therapy despite ongoing drug use.
    Wilkinson M; Crawford V; Tippet A; Jolly F; Turton J; Sims E; Hekker M; Dalton J; Marley R; Foster GR
    Aliment Pharmacol Ther; 2009 Jan; 29(1):29-37. PubMed ID: 18752631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Assessment of quality of life in chronic hepatitis C: effect of treatment].
    Desmorat H; Combis JM; Pradat P
    Gastroenterol Clin Biol; 2003 Dec; 27(12):1084-90. PubMed ID: 14770108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutagenic effects of ribavirin in vivo.
    Perelson AS; Ribeiro RM
    J Hepatol; 2005 Oct; 43(4):553-5. PubMed ID: 16099528
    [No Abstract]   [Full Text] [Related]  

  • 30. [Treatment of chronic hepatitis C: present and future].
    Hezode C; Dhumeaux D
    Gastroenterol Clin Biol; 2000 May; 24(5):533-5. PubMed ID: 10891741
    [No Abstract]   [Full Text] [Related]  

  • 31. [Clinical efficiency of high-dose interferon therapy in patients with chronic NCV hepatitis].
    Nikinin IG; Kuznetsov SL; Kisliakov VA; Ettinger OA; Liuliaeva OD; Storozhakov GI
    Klin Med (Mosk); 1998; 76(11):47-50. PubMed ID: 10050534
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Quality of life of patients with chronic hepatitis C: effect of treatments].
    Couzigou P
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B257-63. PubMed ID: 12180299
    [No Abstract]   [Full Text] [Related]  

  • 33. Patients' preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens.
    Stepanova M; Nader F; Cure S; Bourhis F; Hunt S; Younossi ZM
    Aliment Pharmacol Ther; 2014 Sep; 40(6):676-85. PubMed ID: 25040192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autoimmune manifestations during interferon therapy in patients with chronic hepatitis C: the hepatologist's view.
    Pellicano R; Smedile A; Peyre S; Astegiano M; Saracco G; Bonardi R; Rizzetto M
    Minerva Gastroenterol Dietol; 2005 Mar; 51(1):55-61. PubMed ID: 15756146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Serum intercellular adhesion molecule ICAM-1 concentration in interferon alpha treated patients with chronic viral C hepatitis].
    Warakomska I; Wiczkowski A; Kepa L; Stolarz W; Wilczek K; Błedowski D; Sobala-Szczygieł B; Oczko-Grzesik B; Dziambor AP; Mossor K
    Wiad Lek; 2004; 57(11-12):641-6. PubMed ID: 15865242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Factors of response to treatment with interferon-alpha in patients with chronic hepatitis C. Therapeutic perspectives].
    Marcellin P; Pouteau M; Martinot M; Boyer N; Castelnau C; Benhamou JP; Erlinger S
    Gastroenterol Clin Biol; 1995 Dec; 19(12):991-1000. PubMed ID: 8729410
    [No Abstract]   [Full Text] [Related]  

  • 37. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity.
    McHutchison JG; Ware JE; Bayliss MS; Pianko S; Albrecht JK; Cort S; Yang I; Neary MP;
    J Hepatol; 2001 Jan; 34(1):140-7. PubMed ID: 11211891
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C.
    Hollander A; Foster GR; Weiland O
    Scand J Gastroenterol; 2006 May; 41(5):577-85. PubMed ID: 16638701
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes of hepatic vitronectin levels in patients with chronic hepatitis C treated with interferon alpha.
    Yamada S; Suou T; Kawasaki H; Horie Y; Nagami M; Yashima S; Sugihara C; Tanaka H
    Res Commun Mol Pathol Pharmacol; 1999; 104(3):253-63. PubMed ID: 10741376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis C virus.
    Jarrett M; Cox P
    Nurs Clin North Am; 2004 Mar; 39(1):219-29. PubMed ID: 15062738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.